Meanwell believes that inclisiran can be a very successful drug at a much lower price than Repatha and Praluent.
from Forbes Real Time https://www.forbes.com/sites/johnlamattina/2017/11/09/the-medicines-company-pcsk9-inhibitor-strategy-more-heart-patients-via-lower-pricing/
via IFTTT
No comments:
Post a Comment